Posted on 15th September, 2020
by Legal Staff
Saxagliptin, sold under the brand name Onglyza, is a medication used to control high blood sugar in people who struggle with diabetes. It was approved by the Food and Drug Administration in 2009 for the treatment of type 2 diabetes. However, medical studies found that taking Onglyza on a regular basis can lead to multiple serious health problems, including heart failure.
In 2016, the Food and Drug Administration released a Drug Safety Communication announcing that the drug may cause heart failure in people who take it on a regular basis. Onglyza has been manufactured by AstraZeneca. Furthermore, taking Nesina, medically known as alogliptin, another medication used in the treatment of diabetes, can also result in heart failure. As a DPP-4 inhibitor, Onglyza is prescribed to reduce blood glucose in people with diabetes.
The warning label mentioning heart failure that is now present on Onglyza is the result of the randomized clinical study SAVOR, which was has been conducted for 2 years. Here is what the randomized clinical study of Onglyza found:
It is worthy of note that people who have heart disease or kidney disease have a higher risk of experiencing heart failure if they receive treatment with Onglyza. Thereby, the Food and Drug Administration advises medical professionals to interrupt the treatment if the patient is hospitalized for heart failure as a consequence of taking Onglyza. Heart failure occurs when the heart is unable to pump enough blood through your body. Left untreated, it may be fatal, as the body is not receiving sufficient oxygen and thereby, your vital organs will be affected. It is noteworthy that heart failure is a medical emergency. If you take Onglyza and experience the following symptoms, please seek medical attention immediately, as you may be experiencing heart failure:
It is important to know that there are other medications similar to Onglyza that are also used to control the levels of blood sugar in people with diabetes and that were also associated with a high risk of heart failure, such as:
In February 2018, there were over 80 people who filed a personal injury claim with the manufacturer of Onglyza, AstraZeneca. Nevertheless, the number of claims has been increasing considerably over the last years, since more and more people experience heart failure and other health problems, such as pancreatic cancer, after regularly taking the medication. If you experienced heart failure as a consequence of taking Onglyza, please contact Atraxia Law to see if you are eligible for compensation.
We will promptly review your case, which will take approximately 10 minutes over the phone, and subsequently help you file a claim with AstraZeneca if you qualify for compensation. Within 3 to 6 months, you will receive the money you are entitled to from the liable company, which will also help you afford superior healthcare and treatment.